851 Research news
Some Triple-Negative Breast Cancers Are More Aggressive Than Others

Not all triple-negative breast cancers are the same, with certain subtypes being more aggressive than others, according to a study.

Apr 22, 2021 | Diagnosis
Lynparza Offers Benefits for Early-Stage HER2-Negative Breast Cancer With BRCA1/2 Mutation

Adding Lynparza to standard treatment for early-stage HER2-negative breast cancer with a high risk of recurrence in people with a BRCA1 or BRCA2 mutation improved disease-free survival.

People Taking Hormonal Therapy for Breast Cancer Have Higher Risk of Heart Disease, Monitoring Recommended

People taking hormonal therapy medicine to treat breast or prostate cancer have a higher risk of heart attack and stroke as they get older and should be monitored regularly to detect any problems.

Reducing Treatment Seems Safe for Older Women With Early-Stage, Hormone-Receptor-Positive Breast Cancer

Skipping sentinel lymph node biopsy and/or radiation therapy didn’t affect recurrence rates or survival for women age 70 and older diagnosed with early-stage, hormone-receptor-positive, HER2-negative, clinically node-negative breast cancer.

May 4, 2021 | Diagnosis and Radiation Therapy
Triple-Negative Breast Cancer Deadlier for Black Women, Partially Due to Lower Surgery, Chemotherapy Rates

Black women who are diagnosed with triple-negative breast cancer are 28% more likely to die from the disease than white women with the same diagnosis.

More Than 2 Years of Bisphosphonates for Early-Stage Breast Cancer Doesn't Offer More Benefits

Receiving 3 to 5 years of bisphosphonate treatment after surgery and chemotherapy for early-stage breast cancer doesn’t improve survival any more than receiving 2 years of bisphosphonate treatment.

Jul 2, 2021 | Diagnosis and Bone Health
More Abdominal Fat Linked to Worse Outcomes for Black Women Who Are Breast Cancer Survivors

Black women diagnosed with breast cancer who also have central obesity — excess body fat in the abdominal area — were more likely to die from breast cancer or any other cause than similar women who didn’t have central obesity.

Jun 29, 2021 | Diagnosis, Risk Factors and Ethnicity
Adding Tukysa to Standard of Care Continues To Improve Survival in Advanced-Stage HER2-Positive Breast Cancer

Adding Tukysa to the standard of care of Herceptin and Xeloda continued to improve both progression-free and overall survival in people diagnosed with either metastatic or unresectable locally advanced HER2-positive breast cancer that had been previously treated with Herceptin, Perjeta, and Kadcyla.

Most Women With Metastatic Breast Cancer Have Troubling Treatment Side Effects, Willing To Discuss Dosing Options With Doctor

About 86% of women diagnosed with metastatic breast cancer had at least one bad treatment-related side effect, and 92% were willing to discuss options for different dosing levels of medicines based on their unique situations.

Ultralow MammaPrint Score Means Excellent Breast Cancer Outcomes

People diagnosed with breast cancer who got an ultralow risk of recurrence score on the MammaPrint genomic test had excellent long-term outcomes, whether or not they received hormonal therapy and/or chemotherapy after surgery.

Jun 29, 2021 | Diagnosis
Poor Quality of Life Linked to Stopping Hormonal Therapy Treatment Early

Women who report worse quality of life factors, such as poor physical well-being, poor social well-being, and a history of depression, are more likely to stop hormonal therapy early.

Jul 1, 2021 | Diagnosis and Hormonal Therapy
Trodelvy Improves Outcomes for Previously Treated Metastatic Triple-Negative Breast Cancer

Compared to standard chemotherapy, Trodelvy offered better outcomes for people diagnosed with previously treated metastatic triple-negative breast cancer.

Immunotherapy for Early-Stage Triple-Negative Breast Cancer: Understanding What Appear to Be Conflicting Results

Results from two studies on using the immunotherapy medicines Tecentriq or Keytruda along with chemotherapy to treat early-stage triple-negative breast cancer before surgery suggested that Keytruda offered benefits while Tecentriq did not.

Most Women Don't Get Enough Exercise After Being Diagnosed

About 65% of women diagnosed with breast cancer don't meet national exercise recommendations after they've been diagnosed, and Black women are much less likely to meet exercise recommendations than white women.

Jul 15, 2014 | Diagnosis and Exercise
Electroacupuncture Helps Ease Fatigue, Anxiety, and Depression in Women Taking Aromatase Inhibitors

Electroacupuncture – a type of acupuncture where a small electric current passes between pairs of acupuncture needles – has been found to ease fatigue, anxiety, and depression in women diagnosed with early-stage breast cancer who are taking an aromatase inhibitor.

Full Dose of Radiation Therapy May Not Be Needed for Some Early-Stage Breast Cancers

Early results suggest that treating just the area around where a cancer used to be with radiation may be as good as treating the whole breast with radiation.

Mar 25, 2016 | Diagnosis, Radiation Therapy and Surgery
Shorter Radiation Regimen Causes Fewer Side Effects, Offers Better Quality of Life Than Traditional Regimen

Hypofractionated radiation after lumpectomy offers better quality of life than conventional schedule.

Aug 12, 2015 | Diagnosis and Radiation Therapy
Older Women Report Better Cosmetic Results With Lumpectomy and Brachytherapy

A study suggests that women 67 and older diagnosed with early-stage breast cancer are more satisfied cosmetically with lumpectomy and brachytherapy compared to other treatment options.

Jan 26, 2017 | Diagnosis and Radiation Therapy
Women Older Than 80 Less Likely to Benefit From Chemotherapy

A study has found that women older than 80 diagnosed with early-stage, hormone-receptor-negative breast cancer don't get survival benefits from chemotherapy.

Aug 18, 2015 | Diagnosis and Chemotherapy
Non-White Women Have More Breast Cancer Pain

Non-white women have more severe pain with advanced breast cancer than white women.

Taxotere Combo Improves Survival

The combination of Taxotere (chemical name: docetaxel) and Cytoxan (chemical name: cyclophosphamide) offers better survival and fewer and less severe side effects than the combination of Adriamycin (chemical name: doxorubicin) and Cytoxan for treating breast cancer.

Dec 13, 2007 | Diagnosis and Chemotherapy
Tamoxifen Plus Removing Ovaries Improves Survival for Premenopausal Women

Removing the ovaries and taking tamoxifen after breast cancer surgery had benefits for premenopausal women shows a new study done in Vietnam and China.

Smoking During Breast Cancer Radiation Therapy Increases Risk of Lung Cancer

A new study shows that women who smoked and got radiation therapy to treat breast cancer had a much higher risk of lung cancer later on compared to women who got radiation and didn't smoke.

Infections Following Breast Cancer Surgery More Common Than Expected

While most women having breast cancer surgery won't develop an infection, research shows that infections after breast surgery happen more often than expected.

Showing 24 of 851